This is a multi-center, long-term safety and efficacy follow-up study for participants with cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug Product (eli-cel) in a parent clinical study (Study ALD-102 or Study ALD-104). After completing a parent clinical study (approximately 2 years), eligible participants will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in this study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Major functional disability (MFD)-free survival
Timeframe: 15 years post-drug-product infusion
Number of participants with malignancies
Timeframe: 15 years post-drug-product infusion
Number of participants who experience graft versus host disease (GVHD)
Timeframe: 15 years post-drug-product infusion
Number of participants with immune-related adverse events (AEs)
Timeframe: 15 years post-drug-product infusion
Number of participants with new or worsening hematologic disorders
Timeframe: 15 years post-drug-product infusion
Number of participants with new or worsening neurologic disorders
Timeframe: 15 years post-drug-product infusion